Augment is the leading augmented reality platform. It allows you to visualize your products in 3D in your real environment and in real-time through your tablet or smartphone. From CPGs to architecture and construction to art, Augment is a powerful tool across industry verticals.

Our mission is to seamlessly merge our physical and virtual experiences. Together, we want to change the way people see and imagine the world around them.

Show more
Type
Private
HQ
Paris, FR
Founded
2011
Size (employees)
30 (est)
Augment was founded in 2011 and is headquartered in Paris, FR
Report incorrect company information

Augment Office Locations

Augment has offices in Paris, Orlando and New York
Paris, FR (HQ)
107 Avenue Parmentier
New York, US
79 Madison Ave
Orlando, US
618 37 N Orange Ave
Show all (3)
Report incorrect company information

Augment Financials and Metrics

Summary Metrics

Founding Date

2011

Total Funding

$9.8 m

Latest funding size

$5 m

Time since last funding

9 months ago

Investors

Augment's latest funding round in September 2017 was reported to be $5 m. In total, Augment has raised $9.8 m
Show all financial metrics
Report incorrect company information

Augment Online and Social Media Presence

Embed Graph
Report incorrect company information

Augment News and Updates

At Festival of the Impossible, Artists Augment Reality to Tell Fresh Stories

Getting trippy with storytelling at Festival of the Impossible, an AR and VR showcase currently showing in San Francisco.

Underwater Camera Market: Adventure Tourism Poised to Augment Demand for Better Underwater Photography

Underwater Camera Market is set to be worth US$8946.1 mn by the end of 2025 as compared to US$2109.9 mn in 2015; market for Underwater Camera is expected to surge at a CAGR of 15.63% during the forecast period of 2017 and 2025 Posted via Industry Today. Follow us on Twitter @IndustryToday

Web Analytics Market - Increasing Usage of Smartphones are Projected To Augment The Demand For Web Analytics

Web Analytics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025 Posted via Industry Today. Follow us on Twitter @IndustryToday

Celgene's Revlimid fails lymphoma trial, and it's more than a data shortfall: analyst

On a quest to make Revlimid a go-to drug for non-Hodgkin lymphoma, Celgene paired its longtime blockbuster with Rituxan and pitted the two against Rituxan and standard chemo. It was a risky proposition—and it failed.

Venous Stents Market to Discern Steadfast Expansion at US$1.72 Bn During 2017-2025

Transparency Market Research has announced the addition of the “Venous Stents Market: Global Industry Analysis and Opportunity Assessment, 2017-2025"report to their offering. Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more
Report incorrect company information